In addition, PPAR‐γ agonists have been suggested to reduce the risk of recurrent stroke and total events of cardiovascular death or stroke by protecting against arteriosclerosis formation and maintaining the stability of carotid plaques (J. Liu & Wang, 2019; Marfella et al., 2006). The gene discussed is PPARG; the disease is stroke disorder.